Maxim Kulik/iStock via Getty Images
AbbVie’s (NYSE:ABBV) move to buy New York-based psychedelic drug developer Gilgamesh Pharmaceuticals in a deal worth around $1B, according to Bloomberg News, rallied the psychedelic space on Thursday.
Citing people familiar with the matter, Bloomberg News added that Peter Thiel-backed Atai